Abstract ATPase inhibitory factor 1 (IF1), an inhibitor of the mitochondrial H+-adenosine
triphosphate (ATP) synthase, is putatively involved in tumor progression. This study aimed to …

To investigate the prognostic impact of MET copy number (MET-CN) in patients with non-
small cell lung cancer (NSCLC), we retrospectively reviewed clinical and pathologic data of …

Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–
30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive …

Accumulating studies have confirmed that mammary serine protease inhibitor (MASPIN)
plays an essential role in non-small cell lung cancer (NSCLC). However, results are still …

The assessment of special categories of non–small-cell lung cancer (NSCLC) patients
requires a comprehensive analysis of all factors potentially influencing the daily quality of life …

Next-generation sequencing of primary and metachronous metastatic cancer lesions may
impact patient care. We present a case of relapsed metastatic breast cancer with a dominant …

Radiotherapy in Lung Cancer: Current and Future Role Review Page 1 Radiotherapy in Lung
Cancer: Current and Future Role Lung cancer is known to be the most commonly diag- nosed …

Background: High-level evidence has established well-recognized standard treatment
regimens for patients undergoing palliative chest radiotherapy (RT) for stage IV non–small …

Introduction The role of postoperative radiation therapy (PORT) in patients with completely
resected non-small cell lung cancer (NSCLC) with pathologically involved mediastinal …

Background Small cell lung cancers (SCLC) are tumors of neuroendocrine origin. Previous
in vitro studies from our laboratory showed that SCLC expresses high levels of the …